Glassman Wealth Services Blueprint Medicines Corp Transaction History

Glassman Wealth Services

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 04, 2023	BUY	$37.97 - $50.0 $189 - $250	5 New	5 $0
Q2 2022 Aug 04, 2022	SELL	$45.23 - $70.15 $452 - $701	-10 Reduced 52.63%	9 $0
Q1 2022 Apr 14, 2022	BUY	$54.1 - $110.08 $541 - $1,100	10 Added 111.11%	19 $1,000
Q2 2020 Aug 06, 2020	SELL	$57.09 - $79.27 $57 - $79	-1 Reduced 10.0%	9 $1,000
Q1 2020 May 12, 2020	SELL	$48.11 - $82.22 $288 - $493	-6 Reduced 37.5%	10 $1,000
Q4 2019 Feb 07, 2020	BUY	$66.73 - $82.59 $200 - $247	3 Added 23.08%	16 $1,000
Q2 2019 Aug 08, 2019	BUY	$73.54 - $97.8 $956 - $1,271	13 New	13 $1,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Glassman Wealth Services, based on Form 13F filings with the SEC.

Stay updated on Glassman Wealth Services with notifications on news.